New hope for colorectal cancer: early targeted therapy may extend control
NCT ID NCT04587128
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 33 times
Summary
This study tests whether giving anti-EGFR drugs (panitumumab or cetuximab) early in treatment can help control advanced colorectal cancer that has spread and cannot be removed by surgery. About 34 people with left-sided tumors will receive these targeted therapies to see if the cancer stays stable or shrinks for at least 6 months. The goal is to improve disease control and possibly allow for retreatment later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.